Results 211 to 220 of about 12,265,574 (365)
Determinants of adherence to antihypertensive treatment of adults ≥ 35 years of age [PDF]
Víctor Alfonso Benavides +5 more
openalex
Efficient One‐Pot Synthesis of Benzothiazole Compounds From Vinamidinium Salts
A catalyst‐free one‐pot reaction of vinamidinium salts with benzothiazole hydrazines efficiently produces 1,3‐bis((3‐methylbenzo[d]thiazol‐2(3H)‐ylidene)hydrazineylidene)propan‐2‐ol (BBTA) and 1‐((1Z,3E)‐1‐(dimethylamino)‐3‐(((Z)‐3‐methylbenzo[d]thiazol‐2(3H)‐ylidene)hydrazineylidene)prop‐1‐en‐2‐yl)pyridin‐1‐ium (DMBT) derivatives.This simple method ...
Zeinab khosravi +4 more
wiley +1 more source
Predicting hypotension, syncope, and fracture risk in patients indicated for antihypertensive treatment: the STRATIFY models. [PDF]
Koshiaris C +15 more
europepmc +1 more source
Long‐term remission in gout: Challenges and future opportunities
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley +1 more source
Hepatic fibrosis and metabolic syndrome are more prevalent in PsA patients treated with methotrexate, compared to RA patients. Metabolic syndrome is associated with the risk of hepatic fibrosis in patients diagnosed with PsA and RA even after adjustment forcumulative methotrexate exposure.
Ratchaya Lertnawapan +3 more
wiley +1 more source
Sympathetic Responses to Antihypertensive Treatment Strategies : Implications for the Residual Cardiovascular Risk. [PDF]
Dell'Oro R +3 more
europepmc +1 more source

